https://guineabissauhealthbulletin.com/article/903438283-cacao-bliss-claims-evaluated-the-natural-glp-1-superfood-alternative-earth-echo-s-chocolate-drink-mix-for-weight-loss Guinea Bissau Health Bulletin en PressRelease 2026-04-03T00:10:00+00:00 Cacao Bliss Claims Evaluated: The Natural GLP-1 Superfood Alternative, Earth Echo's Chocolate Drink Mix for Weight Loss https://zingfast.com/wp-content/uploads/2026/04/Cacao-Bliss.jpg https://guineabissauhealthbulletin.com/article/903419453-mesa-labs-declares-quarterly-dividend Guinea Bissau Health Bulletin en PressRelease 2026-04-02T22:00:00+00:00 MESA LABS DECLARES QUARTERLY DIVIDEND https://ml.globenewswire.com/media/ff66b401-9246-47b9-accc-2f553d346c5c/small/mesalogo-jpg.jpg https://guineabissauhealthbulletin.com/article/903419573-merit-medical-systems-to-announce-first-quarter-2026-results-on-april-30-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T22:00:00+00:00 Merit Medical Systems to Announce First Quarter 2026 Results on April 30, 2026 https://ml.globenewswire.com/media/19958d8f-47a4-44f3-a780-247335a68768/small/merit-medical-systems-inc-logo.jpg https://guineabissauhealthbulletin.com/article/903419504-conavi-medical-announces-results-from-its-annual-general-meeting-of-shareholders Guinea Bissau Health Bulletin en PressRelease 2026-04-02T21:44:30+00:00 Conavi Medical Announces Results from Its Annual General Meeting of Shareholders https://ml.globenewswire.com/media/4a28f1c0-f99d-4940-b2a7-201ab98cdaff/small/conavi-jpg.jpg https://guineabissauhealthbulletin.com/article/903419498-newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T21:43:42+00:00 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/f7b8b881-9461-4712-9965-707ed3bdd573/small/newamsterdam-logo-full-color-final-png.png https://guineabissauhealthbulletin.com/article/903418492-information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-company-as-of-march-31-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:30:00+00:00 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 https://ml-eu.globenewswire.com/media/274bd0ae-19c4-4821-85ce-7fe85ee610b5/small/logo1-jpg.jpg https://guineabissauhealthbulletin.com/article/903418496-information-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-31-mars-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:30:00+00:00 Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026 https://ml-eu.globenewswire.com/media/274bd0ae-19c4-4821-85ce-7fe85ee610b5/small/ https://guineabissauhealthbulletin.com/article/903418721-olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:30:00+00:00 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/9c736753-c905-4bd1-ac3a-1444bea84331/small/olema-logo-rgb-png.png https://guineabissauhealthbulletin.com/article/903418919-regeneron-collaborates-with-trinetx-to-access-de-identified-electronic-health-records-of-300-million-patients-to-drive-research-and-product Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:30:00+00:00 Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://guineabissauhealthbulletin.com/article/903419450-serina-therapeutics-announces-nyse-american-acceptance-of-continued-listing-compliance-plan Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:13:00+00:00 Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan https://ml.globenewswire.com/media/7f8e4304-8465-4d4d-a7e3-ebc4eae51f29/small/yellow-burts-blue-text-1-png.png https://guineabissauhealthbulletin.com/article/903418718-rxsight-inc-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:10:00+00:00 RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/48441335-c938-45ff-9355-ba8e331354e9/small/rxsight-globe-png.png https://guineabissauhealthbulletin.com/article/903418651-equillium-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:05:00+00:00 Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/14ce766d-e697-461f-a27c-c1ee49c0eeff/small/equillium-logo-360x180-jpg.jpg https://guineabissauhealthbulletin.com/article/903418710-terns-pharmaceuticals-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:05:00+00:00 Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) https://ml.globenewswire.com/media/cfd0bb0d-8a9b-4de4-92ce-47e8018cf3d9/small/terns-logo-rgbs-jpg.jpg https://guineabissauhealthbulletin.com/article/903418769-relay-therapeutics-to-present-initial-clinical-data-on-zovegalisib-in-vascular-anomalies-at-the-international-society-for-the-study-of-vascular Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:05:00+00:00 Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 https://ml.globenewswire.com/media/079b6db5-ce81-4a81-9cde-d97f86c569ae/small/logo-banner-small-png.png https://guineabissauhealthbulletin.com/article/903418814-fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635-c-4 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:05:00+00:00 Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg https://guineabissauhealthbulletin.com/article/903418840-candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:05:00+00:00 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/8b82e1e3-4a67-4472-a7c8-05f9d24c9bb0/small/candel-logo-fullcolor-4-png.png https://guineabissauhealthbulletin.com/article/903418845-minerva-announces-leadership-transition Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:05:00+00:00 Minerva Announces Leadership Transition https://ml.globenewswire.com/media/69e604cb-25b6-4235-ae9a-17c25cc158b9/small/minerva-logo.jpg https://guineabissauhealthbulletin.com/article/903419076-akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:05:00+00:00 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://guineabissauhealthbulletin.com/article/903398555-fibrobiologics-announces-closing-of-3-million-public-offering Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:01:00+00:00 FibroBiologics Announces Closing of $3 Million Public Offering https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://guineabissauhealthbulletin.com/article/903399500-praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:01:00+00:00 Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://guineabissauhealthbulletin.com/article/903400112-summary-notice-of-pendency-and-proposed-settlement-of-stockholder-derivative-actions Guinea Bissau Health Bulletin en PressRelease 2026-04-02T20:01:00+00:00 Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions https://ml.globenewswire.com/media/3a5f958d-422c-4a97-a96d-cf06f640b587/small/exicure-logo-final-full-color-072515-png.png https://guineabissauhealthbulletin.com/article/903400085-visory-health-se-posiciona-entre-las-principales-tarjetas-de-descuento-para-medicamentos-bajo-prescripci-n-en-estados-unidos-ofreciendo-a-millones-de Guinea Bissau Health Bulletin en PressRelease 2026-04-02T19:40:55+00:00 Visory Health se posiciona entre las principales tarjetas de descuento para medicamentos bajo prescripción en Estados Unidos, ofreciendo a millones de personas acceso a tratamientos asequibles https://ml.globenewswire.com/media/e5a74903-3e24-4101-9d07-c377482b32ec/small/visory-health-logo-png.png https://guineabissauhealthbulletin.com/article/903400069-get-summer-season-ready-with-new-notorious-fitness-training-plans Guinea Bissau Health Bulletin en PressRelease 2026-04-02T19:35:59+00:00 Get Summer-Season Ready with New Notorious Fitness Training Plans https://ml.globenewswire.com/media/485cb087-ce87-45bc-bd40-7b164d7bda7a/small/logo-ni-png.png https://guineabissauhealthbulletin.com/article/903400049-mediwound-reports-barda-contract-award-to-vericel-for-nexobrid-valued-at-up-to-197-million Guinea Bissau Health Bulletin en PressRelease 2026-04-02T19:26:11+00:00 MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million https://ml.globenewswire.com/media/55509183-b8b9-4da4-ae63-92c83760b5d9/small/mdwd-logo-jpg.jpg https://guineabissauhealthbulletin.com/article/903399638-vericel-announces-barda-award-valued-at-up-to-197-million-for-procurement-and-advanced-development-of-nexobrid Guinea Bissau Health Bulletin en PressRelease 2026-04-02T18:40:00+00:00 Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid https://ml.globenewswire.com/media/6a144258-8523-493f-8a1e-ccceec233208/small/vericel-corporation-logo.jpg https://guineabissauhealthbulletin.com/article/903382944-cherry-picking-science-wva-condemns-eu-tobacco-report Guinea Bissau Health Bulletin en PressRelease 2026-04-02T16:39:14+00:00 Cherry-Picking Science: WVA Condemns EU Tobacco Report https://ml.globenewswire.com/media/23d44cef-b934-4430-a66e-f7a36a326666/medium/world-vapers-alliance.jpeg https://guineabissauhealthbulletin.com/article/903380596-genfit-r-sultats-financiers-annuels-2025-et-point-sur-les-activit-s-de-la-soci-t Guinea Bissau Health Bulletin en PressRelease 2026-04-02T16:30:20+00:00 GENFIT : Résultats financiers annuels 2025 et point sur les activités de la Société   https://ml-eu.globenewswire.com/media/ZTkzMGRhNzItOGJkZS00NWRhLTllNWYtY2RmZmVhMWVlNTZiLTEwMTEyNjgtMjAyNi0wNC0wMi1mcg==/tiny/GENFIT-S-A-.png https://guineabissauhealthbulletin.com/article/903380643-genfit-reports-full-year-2025-financial-results-and-provides-corporate-update Guinea Bissau Health Bulletin en PressRelease 2026-04-02T16:30:20+00:00 GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update   https://ml-eu.globenewswire.com/media/ZTkzMGRhNzItOGJkZS00NWRhLTllNWYtY2RmZmVhMWVlNTZiLTEwMTEyNjgtMjAyNi0wNC0wMi1lbg==/tiny/GENFIT-S-A-.png https://guineabissauhealthbulletin.com/article/903380423-medicana-health-group-marks-world-autism-awareness-day-with-a-call-for-inclusion-earlier-recognition-and-family-centered-support Guinea Bissau Health Bulletin en PressRelease 2026-04-02T16:00:00+00:00 Medicana Health Group Marks World Autism Awareness Day with a Call for Inclusion, Earlier Recognition and Family-Centered Support  https://ml-eu.globenewswire.com/media/4552042c-da21-40b5-90e7-122b99c64bff/medium/medicana-atakoy-hospital.png https://guineabissauhealthbulletin.com/article/903381718-eylea-hd-aflibercept-approved-by-fda-as-first-and-only-injectable-anti-vegf-with-dosing-intervals-up-to-5-months-for-wet-age-related-macular Guinea Bissau Health Bulletin en PressRelease 2026-04-02T16:00:00+00:00 EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://guineabissauhealthbulletin.com/article/903360628-liv-hospital-highlights-hospital-based-stem-cell-infrastructure-during-autism-awareness-month Guinea Bissau Health Bulletin en PressRelease 2026-04-02T15:00:00+00:00 Liv Hospital Highlights Hospital-Based Stem Cell Infrastructure During Autism Awareness Month https://ml-eu.globenewswire.com/media/56455831-7774-4cd6-b91c-6ed239d89950/medium/liv-hospital-highlights-hospital-based-stem-cell-infrastruct.jpg https://guineabissauhealthbulletin.com/article/903363207-global-virus-network-meeting-advances-a-science-driven-agenda-for-pandemic-preparedness Guinea Bissau Health Bulletin en PressRelease 2026-04-02T15:00:00+00:00 Global Virus Network Meeting Advances a Science-Driven Agenda for Pandemic Preparedness https://ml.globenewswire.com/media/6c1b2724-7b9b-469a-a7c3-bc0a64d716ae/small/gvn-lt-gr-gradiant-jpg.jpg https://guineabissauhealthbulletin.com/article/903364235-abbvie-ibd-scholarship-program-marks-15-years-applications-open-for-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T15:00:00+00:00 AbbVie IBD Scholarship Program Marks 15 Years: Applications Open for 2026 https://ml.globenewswire.com/media/d853f38f-4056-484f-94ad-0d49eccd29ee/small/ccc-logo-pr-png.png https://guineabissauhealthbulletin.com/article/903364241-le-programme-de-bourses-d-tudes-mii-d-abbvie-f-te-ses-15-ans-les-candidatures-sont-ouvertes-pour-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T15:00:00+00:00 Le programme de bourses d'études MII d’AbbVie fête ses 15 ans : les candidatures sont ouvertes pour 2026 https://ml.globenewswire.com/media/d853f38f-4056-484f-94ad-0d49eccd29ee/small/ https://guineabissauhealthbulletin.com/article/903360645-assisted-reproductive-technology-market-set-to-reach-6-02-billion-by-2030-marketsandmarkets Guinea Bissau Health Bulletin en PressRelease 2026-04-02T14:30:00+00:00 Assisted Reproductive Technology Market Set to Reach $6.02 Billion by 2030 | MarketsandMarkets™ https://ml.globenewswire.com/media/afcc5182-4ae0-43a8-a965-4351d590b7ed/small/mnm-logo-tm-jpg-jpg.JPG https://guineabissauhealthbulletin.com/article/903363417-paul-markovich-discusses-healthcare-reform-through-the-worthy-movement-on-yourupdatetv Guinea Bissau Health Bulletin en PressRelease 2026-04-02T14:12:48+00:00 Paul Markovich Discusses Healthcare Reform Through the Worthy Movement on YourUpdateTV https://ml.globenewswire.com/media/5115f449-412d-4a05-bbcb-add09b3f2838/small/blank-logo-png.png https://guineabissauhealthbulletin.com/article/903362971-biocardia-files-request-for-meeting-with-fda-to-discuss-accelerated-approval-pathway-for-cardiamp-system-in-ischemic-heart-failure Guinea Bissau Health Bulletin en PressRelease 2026-04-02T14:11:34+00:00 BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure https://ml.globenewswire.com/media/4641bb53-4913-4654-a337-79383a5c7ab9/small/biocardia-final-logo-2016-jpeg-jpg.jpg https://guineabissauhealthbulletin.com/article/903362873-visory-health-ranks-among-top-u-s-prescription-cards-providing-millions-of-americans-access-to-affordable-medications Guinea Bissau Health Bulletin en PressRelease 2026-04-02T14:11:09+00:00 Visory Health Ranks Among Top U.S. Prescription Cards Providing Millions of Americans Access to Affordable Medications https://ml.globenewswire.com/media/e5a74903-3e24-4101-9d07-c377482b32ec/small/visory-health-logo-png.png https://guineabissauhealthbulletin.com/article/903362348-curonix-llc-announces-expanded-reimbursement-coverage-for-freedom-peripheral-nerve-stimulator-pns-system-providing-access-to-an-additional-27 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T14:00:00+00:00 Curonix LLC Announces Expanded Reimbursement Coverage for Freedom® Peripheral Nerve Stimulator (PNS) System, Providing Access To An Additional 27 Million Covered Lives Nationwide https://ml.globenewswire.com/media/6eea76ae-3d4d-421b-886f-9e9da10f08bf/small/curonix-primarylogo-cmyk-png.png https://guineabissauhealthbulletin.com/article/903362591-geneproof-announces-cmv-ivdr-launch-on-the-mycrobe-fully-automated-system-for-transplant-care Guinea Bissau Health Bulletin en PressRelease 2026-04-02T13:59:06+00:00 GeneProof Announces CMV IVDR Launch on the myCROBE™ Fully Automated System for Transplant Care https://ml.globenewswire.com/media/MDJlNGYyYTgtNjZhNC00MmIxLTgwYmQtNzVjMDg5MDk1MTM3LTUwMDE2MDU3Mi0yMDI2LTA0LTAyLWVu/tiny/GeneProof-part-of-NuvinkaDX.png https://guineabissauhealthbulletin.com/article/903362218-mimedx-to-sponsor-leading-advanced-wound-care-conferences Guinea Bissau Health Bulletin en PressRelease 2026-04-02T13:15:00+00:00 MIMEDX to Sponsor Leading Advanced Wound Care Conferences https://ml.globenewswire.com/media/2a60ab36-4917-479c-b53a-4f2113ca347d/small/mimedx-png.png https://guineabissauhealthbulletin.com/article/903344419-global-flexible-pcb-market-to-nearly-double-reaching-41-7-billion-by-2030-on-surging-demand-from-consumer-electronics-evs-and-5g-infrastructure Guinea Bissau Health Bulletin en PressRelease 2026-04-02T13:06:30+00:00 Global Flexible PCB Market to Nearly Double, Reaching $41.7 Billion by 2030 on Surging Demand from Consumer Electronics, EVs and 5G Infrastructure https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://guineabissauhealthbulletin.com/article/903343209-from-lab-fiber-to-luxury-fabric-kraig-biocraft-laboratories-targets-apparel-first-with-engineered-spider-silk Guinea Bissau Health Bulletin en PressRelease 2026-04-02T13:05:00+00:00 From Lab Fiber to Luxury Fabric: Kraig Biocraft Laboratories Targets Apparel First with Engineered Spider Silk https://ml.globenewswire.com/media/ZWEyZTUxNjctYmYxZS00MzM1LWI4ODYtZDFiMjc0ZjU5YTY5LTUwMDE1MTA3NC0yMDI2LTA0LTAyLWVu/tiny/24-7-Market-News-and-Kraig-Lab.png https://guineabissauhealthbulletin.com/article/903343771-sienna-announces-first-quarter-2026-results-release-date-and-conference-call Guinea Bissau Health Bulletin en PressRelease 2026-04-02T13:00:00+00:00 Sienna Announces First Quarter 2026 Results Release Date and Conference Call https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://guineabissauhealthbulletin.com/article/903343778-prenetics-announces-nba-champion-and-two-time-mvp-giannis-antetokounmpo-as-im8-global-partner-and-shareholder-in-multi-year-partnership Guinea Bissau Health Bulletin en PressRelease 2026-04-02T13:00:00+00:00 Prenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership https://ml.globenewswire.com/media/bc89f070-b05a-450e-8fbe-c22e860740da/medium/giannis-im8.jpg https://guineabissauhealthbulletin.com/article/903341669-protecting-healthy-futures-unity-consortium-urges-families-to-prioritize-adolescent-health-during-immunization-action-week Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:55:00+00:00 Protecting Healthy Futures: Unity Consortium Urges Families to Prioritize Adolescent Health During Immunization Action Week https://ml.globenewswire.com/media/2b3eeef1-5425-448e-bb1f-18115321d7a8/small/unity-logo-horiz-png.png https://guineabissauhealthbulletin.com/article/903341881-dr-joseph-mikhael-steps-into-new-role-as-medical-advisor-for-the-international-myeloma-foundation Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:45:00+00:00 Dr. Joseph Mikhael Steps into New Role as Medical Advisor for the International Myeloma Foundation https://ml.globenewswire.com/media/f70068f9-568b-4858-8283-3c96a2db91d6/small/imf-logo-png.png https://guineabissauhealthbulletin.com/article/903343796-entera-bio-announces-pricing-of-10-0-million-direct-investment-by-bvf-partners-with-potential-for-up-to-24-5-million-in-total-proceeds Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:45:00+00:00 Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds https://ml.globenewswire.com/media/9b4ae2bf-733d-4180-b48c-d0fa3f26c81a/small/logo-png.png https://guineabissauhealthbulletin.com/article/903344079-catalyst-medtech-announces-acquisition-of-x3d Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:39:45+00:00 Catalyst MedTech Announces Acquisition of X3D https://ml.globenewswire.com/media/NTczOTM3ZWYtMGI1YS00ZTAyLWE5NGEtN2ZkZmI1MTFmZjhjLTEzMTYxMTAtMjAyNi0wNC0wMi1lbg==/tiny/Catalyst-MedTech.png https://guineabissauhealthbulletin.com/article/903344092-practicelink-reveals-evolved-brand-identity-focused-on-clarity-simplicity-and-trust-for-healthcare-providers-and-recruiters Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:34:44+00:00 PracticeLink Reveals Evolved Brand Identity Focused on Clarity, Simplicity and Trust for Healthcare Providers and Recruiters https://ml.globenewswire.com/media/4489702d-d167-45a5-8e6b-873bd89d1590/small/2026-practicelink-logo-vertical-clr-png.png https://guineabissauhealthbulletin.com/article/903341101-biodexa-announces-partnership-with-syngene-to-manufacture-mtx240-gmp-clinical-trial-supplies Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:30:00+00:00 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies https://ml-eu.globenewswire.com/media/8367259c-e117-4264-9988-26f7e36b032f/small/biodexa-logo-square-1-png.png https://guineabissauhealthbulletin.com/article/903341980-intelligent-bio-solutions-completes-clinical-cut-off-study-advances-fda-510-k-clinical-program-targeting-multi-billion-dollar-u-s-drug-screening Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:30:00+00:00 Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market https://ml.globenewswire.com/media/d4eaef42-9420-48b7-8019-0285720d678c/small/ibs-primary-logo-blue-png.png https://guineabissauhealthbulletin.com/article/903342712-ultragenyx-announces-u-s-fda-acceptance-of-bla-resubmission-for-ux111-aav-gene-therapy-to-treat-sanfilippo-syndrome-type-a-mps-iiia Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:30:00+00:00 Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) https://ml.globenewswire.com/media/121a9bda-7a64-41f8-85e8-1693a2dfa977/small/ultragenyx-cmyk-png.png https://guineabissauhealthbulletin.com/article/903342973-abeona-therapeutics-announces-new-qualified-treatment-center-for-zevaskyn-in-new-york Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:30:00+00:00 Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York https://ml.globenewswire.com/media/f11f9f14-9744-4666-aef3-9771488c41bd/small/thumb-1740-12-silhouette-vertical-full-color-png.png https://guineabissauhealthbulletin.com/article/903343218-onconetix-highlights-realbotix-ai-humanoid-robot-delivery-update Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:30:00+00:00 Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update https://ml.globenewswire.com/media/4824d51d-2ecb-4f49-8b75-fe9b920e7b1c/small/onconetix-logo-jpg.jpg https://guineabissauhealthbulletin.com/article/903343227-oncotelic-therapeutics-announces-strategic-partnership-with-techforce-robotics-to-commercialize-pdaoai-enhanced-gmp-robotics-platform Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:30:00+00:00 Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform https://ml.globenewswire.com/media/aa650511-a1c3-496e-803a-448d7f8d409a/small/picture1-jpg.jpg https://guineabissauhealthbulletin.com/article/903343744-sienna-completes-acquisition-in-greater-toronto-area Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:30:00+00:00 Sienna Completes Acquisition in Greater Toronto Area https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://guineabissauhealthbulletin.com/article/903341404-nanox-signs-distribution-agreement-with-integrity-medical-service-inc-to-deploy-nanox-arc-systems Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:11:00+00:00 Nanox Signs Distribution Agreement with Integrity Medical Service, Inc. to Deploy Nanox.ARC Systems https://ml-eu.globenewswire.com/media/7a1764f8-84e3-4b28-ae23-9add5d57c378/small/nanox-logo-4-png.png https://guineabissauhealthbulletin.com/article/903342205-curanex-expands-its-drug-development-pipeline-to-include-cancer-cachexia-representing-a-multi-billion-dollar-market-opportunity-and-important-step-in Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:07:00+00:00 Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company https://ml.globenewswire.com/media/29bc3de5-6a82-4a17-a165-6a79eef16d74/small/logo-png.png https://guineabissauhealthbulletin.com/article/903341085-mdic-appoints-philips-chief-medical-officer-carla-goulart-peron-as-new-board-member Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:00:00+00:00 MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member https://ml-eu.globenewswire.com/media/e5826782-01bc-45e7-b448-9ca1eae0125e/small/philips-logo-logotype-emblem-700x128-png.png https://guineabissauhealthbulletin.com/article/903341734-picard-medical-syncardia-coo-to-deliver-keynote-at-venture-caf-phoenix-during-arizona-tech-week Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:00:00+00:00 Picard Medical / SynCardia COO to Deliver Keynote at Venture Café Phoenix During Arizona Tech Week https://ml.globenewswire.com/media/93c733bb-b54a-41af-856b-6d01c1f724a2/small/syncardia-x-picard-email-signature-2025-1-png.png https://guineabissauhealthbulletin.com/article/903341755-tvardi-therapeutics-to-participate-in-the-raymond-james-biotech-innovation-symposium Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:00:00+00:00 Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium https://ml.globenewswire.com/media/65859e40-e7db-474e-b604-78033b160f6b/small/tvardi-therapeutics-logo-1200-jpg.jpg https://guineabissauhealthbulletin.com/article/903341946-catheter-precision-engages-strategic-advisor Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:00:00+00:00 Catheter Precision Engages Strategic Advisor https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://guineabissauhealthbulletin.com/article/903341989-calidi-biotherapeutics-to-present-new-data-on-its-lead-asset-cld-401-at-the-aacr-annual-meeting-in-april-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:00:00+00:00 Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://guineabissauhealthbulletin.com/article/903342225-emergent-biosolutions-participates-in-upcoming-international-preparedness-conferences Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:00:00+00:00 Emergent BioSolutions Participates in Upcoming International Preparedness Conferences https://ml.globenewswire.com/media/56a9097d-af91-4bcf-8c42-5905e1614ef1/small/emerge-png.png https://guineabissauhealthbulletin.com/article/903342277-cocrystal-pharma-receives-fda-fast-track-designation-for-cdi-988-for-norovirus-infection-treatment-and-preventive Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:00:00+00:00 Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive https://ml.globenewswire.com/media/a5071a3a-c592-43ba-bfee-77c2867982ba/small/cocrystal-logo-final-highres-792x612-png.png https://guineabissauhealthbulletin.com/article/903342676-milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:00:00+00:00 Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/49b2e16b-2deb-4c9e-9c20-6cc4fd6c15ab/small/milestone-pharmaceuticals-logo-png.png https://guineabissauhealthbulletin.com/article/903343297-bionano-announces-publication-from-johns-hopkins-and-md-anderson-showing-that-ogm-can-outperform-traditional-methods-in-analysis-of-multiple-myeloma Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:00:00+00:00 Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma https://ml.globenewswire.com/media/5ba4072e-6e59-46e7-847c-6aaf7755bbbf/small/bionano-rgb-png.png https://guineabissauhealthbulletin.com/article/903343298-revolution-medicines-begins-treating-patients-in-phase-3-rasolute-303-trial-evaluating-daraxonrasib-as-first-line-treatment-for-patients-with Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:00:00+00:00 Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer  https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://guineabissauhealthbulletin.com/article/903343584-commure-introduces-dictation-ai-powered-clinical-voice-now-at-the-cursor Guinea Bissau Health Bulletin en PressRelease 2026-04-02T12:00:00+00:00 Commure Introduces Dictation: AI-Powered Clinical Voice, Now at the Cursor https://ml.globenewswire.com/media/1136e76f-ef70-46bf-997e-5f9b1b8b2ff6/small/commure-logo-full-horizontal-black-3-png.png https://guineabissauhealthbulletin.com/article/903341778-plus-therapeutics-secures-highmark-coverage-for-cnside-csf-assay-expanding-reimbursement-to-75-million-covered-lives Guinea Bissau Health Bulletin en PressRelease 2026-04-02T11:30:00+00:00 Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives https://ml.globenewswire.com/media/92d7aa70-e37d-4870-bccf-d83b68ba5612/small/plus-logo-png.png https://guineabissauhealthbulletin.com/article/903341792-mink-therapeutics-to-present-new-data-at-asgct-2026-highlighting-context-dependent-activity-of-inkt-cell-therapy Guinea Bissau Health Bulletin en PressRelease 2026-04-02T11:30:00+00:00 MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy https://ml.globenewswire.com/media/6aa8e960-515a-40d6-9894-39ca47f5c84e/small/mink-logo-loyal-blue-and-light-blue-png.png https://guineabissauhealthbulletin.com/article/903342388-context-therapeutics-announces-ctim-76-receives-fda-fast-track-designation-for-the-treatment-of-platinum-resistant-ovarian-cancer Guinea Bissau Health Bulletin en PressRelease 2026-04-02T11:30:00+00:00 Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer https://ml.globenewswire.com/media/67b45666-397e-4c48-af45-ffd653bbfddf/small/context-therapeutics-inc.jpg https://guineabissauhealthbulletin.com/article/903342707-annovis-secures-u-s-patent-for-buntanetap-in-the-prevention-and-treatment-of-neurological-injuries-caused-by-brain-infections Guinea Bissau Health Bulletin en PressRelease 2026-04-02T11:30:00+00:00 Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections https://ml.globenewswire.com/media/7ee459df-d33f-4f42-b27c-3bd20487d50c/small/annovis-corp-image-png.png https://guineabissauhealthbulletin.com/article/903342662-cylinder-health-launches-stool-scan-to-innovate-and-standardize-one-of-gi-care-s-most-subjective-signals Guinea Bissau Health Bulletin en PressRelease 2026-04-02T11:10:00+00:00 Cylinder Health launches Stool Scan to innovate and standardize one of GI care’s most subjective signals https://ml.globenewswire.com/media/cfb89636-f442-479b-87c5-e2c3f43b777c/small/main-cylinder-wordmark-rgb-black-png.png https://guineabissauhealthbulletin.com/article/903343341-adagene-announces-pricing-of-us-70-0-million-public-offering-of-adss Guinea Bissau Health Bulletin en PressRelease 2026-04-02T11:10:00+00:00 Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://guineabissauhealthbulletin.com/article/903342592-cartesian-therapeutics-announces-new-employment-inducement-grants Guinea Bissau Health Bulletin en PressRelease 2026-04-02T11:05:00+00:00 Cartesian Therapeutics Announces New Employment Inducement Grants https://ml.globenewswire.com/media/2bf78841-be30-4bb5-bfb5-0b5f383f3302/small/cartesian-logo-color-png.png https://guineabissauhealthbulletin.com/article/903343176-adagene-announces-clinical-collaboration-with-incyte-to-evaluate-muzastotug-adg126-in-combination-with-incyte-s-tgf-r2xpd-1-bispecific-antibody Guinea Bissau Health Bulletin en PressRelease 2026-04-02T11:01:00+00:00 Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://guineabissauhealthbulletin.com/article/903342811-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-late-line-patients-with-microsatellite-stable Guinea Bissau Health Bulletin en PressRelease 2026-04-02T11:00:00+00:00 Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://guineabissauhealthbulletin.com/article/903342871-neutrolis-announces-positive-first-in-human-phase-1a-results-from-liberate-i-trial-of-ntr-1011-a-first-in-class-dnase1l3-fusion-protein Guinea Bissau Health Bulletin en PressRelease 2026-04-02T11:00:00+00:00 Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein https://ml.globenewswire.com/media/44cdba09-fdb9-4ee1-b7bf-1dcfe5784800/small/20180228-opr-or-logos-biz-wd-neutrolis-logo-1-jpg.jpg https://guineabissauhealthbulletin.com/article/903343172-skye-bioscience-treats-first-patient-in-nimacimab-higher-dose-expansion-study-evaluating-exposure-response-to-inform-phase-2b-dose-selection-for-glp-1 Guinea Bissau Health Bulletin en PressRelease 2026-04-02T11:00:00+00:00 Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development https://ml.globenewswire.com/media/905e06d8-af43-4f7a-b097-8c12ce1d3aa0/small/skye-darkblue-jpg.jpg https://guineabissauhealthbulletin.com/article/903321591-pharvaris-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update Guinea Bissau Health Bulletin en PressRelease 2026-04-02T10:50:00+00:00 Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png https://guineabissauhealthbulletin.com/article/903321923-burning-rock-announces-founder-s-purchase-of-its-adss Guinea Bissau Health Bulletin en PressRelease 2026-04-02T10:25:59+00:00 Burning Rock Announces Founder’s Purchase of Its ADSs https://ml.globenewswire.com/media/904d8c1b-eae2-4b6f-83ed-3cb8d0ad31f6/small/logo-01-png.png https://guineabissauhealthbulletin.com/article/903321555-arch-biopartners-closes-non-brokered-private-placement Guinea Bissau Health Bulletin en PressRelease 2026-04-02T09:45:00+00:00 Arch Biopartners Closes Non-Brokered Private Placement https://ml.globenewswire.com/media/8fae7e83-0899-4bbc-ba40-0250cdb9aea7/small/logo-png.png https://guineabissauhealthbulletin.com/article/903321482-roivant-announces-expansion-of-brepocitinib-development-program-with-new-phase-2b-3-trial-in-lichen-planopilaris-lpp-and-phase-3-study-results-for Guinea Bissau Health Bulletin en PressRelease 2026-04-02T09:00:00+00:00 Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) https://ml.globenewswire.com/media/f1a5db68-ee4f-437f-b4e6-2b840ae6a536/small/roivantlogo-png.png https://guineabissauhealthbulletin.com/article/903321557-priovant-expands-brepocitinib-development-program-with-new-phase-2b-3-trial-in-lichen-planopilaris-lpp Guinea Bissau Health Bulletin en PressRelease 2026-04-02T09:00:00+00:00 Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) https://ml.globenewswire.com/media/OTFhNWNlNjItZDZhZC00NWMwLTg1ZDEtMDE5MGI1ODhhYjZjLTEwMzAxODQtMjAyNi0wNC0wMi1lbg==/tiny/Roivant-Sciences-Inc-.png https://guineabissauhealthbulletin.com/article/903321596-immunovant-announces-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted Guinea Bissau Health Bulletin en PressRelease 2026-04-02T09:00:00+00:00 Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) https://ml.globenewswire.com/media/7062c765-82cc-4ba2-ba1f-4b1396b9b052/small/immulogo-jpg.jpg https://guineabissauhealthbulletin.com/article/903303851-mygevity-announces-nationwide-launch-of-integrated-health-data-platform Guinea Bissau Health Bulletin en PressRelease 2026-04-02T08:31:46+00:00 MyGevity Announces Nationwide Launch of Integrated Health Data Platform https://ml.globenewswire.com/Resource/Download/57c484c8-5351-4c6a-9b57-34085204291c/image1.png https://guineabissauhealthbulletin.com/article/903247534-celldex-announces-pricing-of-300-million-public-offering-of-common-stock Guinea Bissau Health Bulletin en PressRelease 2026-04-02T01:48:19+00:00 Celldex Announces Pricing of $300 Million Public Offering of Common Stock https://ml.globenewswire.com/media/7a6cc287-087f-4e97-878f-7c1ed1dc5949/small/celldex-logo-rgb-png.png https://guineabissauhealthbulletin.com/article/903247472-metatrim-bhb-claims-evaluated-the-quick-burn-keto-bhb-formula-everyone-is-researching-meta-trim-ketones Guinea Bissau Health Bulletin en PressRelease 2026-04-02T01:34:30+00:00 MetaTrim BHB Claims Evaluated: The Quick Burn Keto BHB Formula Everyone is Researching, Meta Trim Ketones https://zingfast.com/wp-content/uploads/2026/04/MetaTrim-BHB.jpg https://guineabissauhealthbulletin.com/article/903247452-good-oral-health-isn-t-complicated-alberta-s-dentists-want-you-to-know-what-works Guinea Bissau Health Bulletin en PressRelease 2026-04-02T01:10:54+00:00 Good oral health isn't complicated — Alberta's dentists want you to know what works https://ml.globenewswire.com/media/caec844b-ce06-4a8a-8b80-a9cc1fb1337e/small/ada-rgb-colour-highres-png.png https://guineabissauhealthbulletin.com/article/903230162-telix-appoints-david-gill-as-non-executive-director Guinea Bissau Health Bulletin en PressRelease 2026-04-01T23:53:07+00:00 Telix Appoints David Gill as Non-Executive Director https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://guineabissauhealthbulletin.com/article/903215210-beam-therapeutics-announces-publication-of-beacon-phase-1-2-data-for-risto-cel-in-patients-with-sickle-cell-disease-scd-in-the-new-england-journal Guinea Bissau Health Bulletin en PressRelease 2026-04-01T21:12:19+00:00 Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine https://ml.globenewswire.com/media/03af3276-c254-436a-b40d-2ad9a1025f95/small/beamlogo-color-cmyk-jpg.jpg https://guineabissauhealthbulletin.com/article/903213980-adagene-reports-full-year-2025-financial-results-and-provides-corporate-update Guinea Bissau Health Bulletin en PressRelease 2026-04-01T21:00:00+00:00 Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://guineabissauhealthbulletin.com/article/903214873-zentalis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Guinea Bissau Health Bulletin en PressRelease 2026-04-01T21:00:00+00:00 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/1b481d6d-51c9-44f0-b33f-81feb1061d2e/small/zentalis-logo-png.png https://guineabissauhealthbulletin.com/article/903215040-vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Guinea Bissau Health Bulletin en PressRelease 2026-04-01T21:00:00+00:00 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/dde67700-b1b4-40c4-b930-13bd71804762/small/vor-wordmark-rgb-fullcolor-070920-png.png https://guineabissauhealthbulletin.com/article/903214932-pennant-acquires-arbor-rose-senior-living-community-in-mesa-arizona Guinea Bissau Health Bulletin en PressRelease 2026-04-01T20:53:32+00:00 Pennant Acquires Arbor Rose Senior Living Community in Mesa, Arizona https://ml.globenewswire.com/media/d50f543c-fc54-437d-8007-600644587dfe/small/pennant-logo-png.png https://guineabissauhealthbulletin.com/article/903215016-herz-p1-brand-under-investigation-review-the-herz-smart-ring-p1-smart-band-smart-p1-body-scale-product-details Guinea Bissau Health Bulletin en PressRelease 2026-04-01T20:38:44+00:00 Herz P1 Brand Under Investigation: Review the Herz Smart Ring, P1 Smart Band & Smart P1 Body Scale Product Details https://zingfast.com/wp-content/uploads/2026/04/Herz-P1-Brand-Review.jpg https://guineabissauhealthbulletin.com/article/903196369-abivax-publishes-financial-reports-with-the-french-and-u-s-securities-regulatory-agencies Guinea Bissau Health Bulletin en PressRelease 2026-04-01T20:05:00+00:00 Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://guineabissauhealthbulletin.com/article/903196587-sight-sciences-interventional-technologies-for-glaucoma-and-dry-eye-disease-to-be-featured-in-multiple-clinical-presentations-at-the-2026-american Guinea Bissau Health Bulletin en PressRelease 2026-04-01T20:05:00+00:00 Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting https://ml.globenewswire.com/media/e7536623-9fa4-42d0-896d-04ddb984ef4e/small/sght-logo-png.png https://guineabissauhealthbulletin.com/article/903196986-resmed-to-report-third-quarter-fiscal-2026-earnings-on-april-30-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-01T20:05:00+00:00 Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026 https://ml.globenewswire.com/media/fb7a34f4-d074-4bcf-b827-7a6a60924c46/small/resmed-h-pos-clr-rgb-250121-png.png https://guineabissauhealthbulletin.com/article/903197143-akebia-therapeutics-appoints-biopharmaceutical-leader-philip-vickers-ph-d-to-its-board-of-directors Guinea Bissau Health Bulletin en PressRelease 2026-04-01T20:05:00+00:00 Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://guineabissauhealthbulletin.com/article/903196814-carlsmed-inc-to-participate-in-the-25th-annual-needham-virtual-conference Guinea Bissau Health Bulletin en PressRelease 2026-04-01T20:01:00+00:00 Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference https://ml.globenewswire.com/media/ee16eff2-e0d6-40ca-95c5-4dd84bb4cc5f/small/carlsmed-png.png https://guineabissauhealthbulletin.com/article/903197587-celldex-announces-proposed-public-offering-of-common-stock Guinea Bissau Health Bulletin en PressRelease 2026-04-01T20:01:00+00:00 Celldex Announces Proposed Public Offering of Common Stock https://ml.globenewswire.com/media/7a6cc287-087f-4e97-878f-7c1ed1dc5949/small/celldex-logo-rgb-png.png https://guineabissauhealthbulletin.com/article/903197786-berberine-weight-loss-patches-by-purisaki-under-investigation-urgent-warning-issued Guinea Bissau Health Bulletin en PressRelease 2026-04-01T19:52:45+00:00 Berberine Weight Loss Patches by Purisaki Under Investigation (URGENT Warning Issued) https://zingfast.com/wp-content/uploads/2026/04/Berberine-Weight-Loss-Patches-by-Purisaki.jpg https://guineabissauhealthbulletin.com/article/903181712-renovorx-named-to-fast-company-s-annual-list-of-the-world-s-most-innovative-companies-of-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-01T18:20:16+00:00 RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 https://ml.globenewswire.com/media/e18bf823-ff44-4bbd-82b9-3a311d58dad8/small/final-logo-horizontal-png.png https://guineabissauhealthbulletin.com/article/903181579-cloud-computing-in-cell-biology-genomics-and-drug-development-to-reach-15-6-billion-by-2030-as-biological-data-explosion-drives-demand Guinea Bissau Health Bulletin en PressRelease 2026-04-01T17:47:07+00:00 Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://guineabissauhealthbulletin.com/article/903181152-xortx-confirms-effective-date-of-share-consolidation Guinea Bissau Health Bulletin en PressRelease 2026-04-01T17:00:00+00:00 XORTX Confirms Effective Date of Share Consolidation https://ml.globenewswire.com/media/9898c4f8-b373-438a-abfa-709c4372a061/small/xortx-logo-jpg.jpg https://guineabissauhealthbulletin.com/article/903165731-chemed-to-report-first-quarter-2026-earnings-april-23-related-conference-call-to-be-held-on-april-24 Guinea Bissau Health Bulletin en PressRelease 2026-04-01T16:00:00+00:00 Chemed To Report First Quarter 2026 Earnings April 23, Related Conference Call To Be Held On April 24 https://ml.globenewswire.com/media/1ab951c0-8d76-40e0-bc65-ebeaa1731e66/small/chemed-corp-logo-600x400-jpg.jpg https://guineabissauhealthbulletin.com/article/903166771-diagnos-successfully-completes-the-renewal-of-us-fda-medical-device-establishment-registration Guinea Bissau Health Bulletin en PressRelease 2026-04-01T15:50:37+00:00 DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration https://ml.globenewswire.com/media/aaea38c5-db20-4091-bd36-338d3bb064d1/small/diagnos-logo-en-transparent-png.png https://guineabissauhealthbulletin.com/article/903166885-diagnos-compl-te-avec-succ-s-le-processus-de-renouvellement-d-enregistrement-d-tablissement-aupr-s-de-la-us-fda Guinea Bissau Health Bulletin en PressRelease 2026-04-01T15:50:37+00:00 DIAGNOS complète avec succès le processus de renouvellement d’enregistrement d’établissement auprès de la US-FDA https://ml.globenewswire.com/media/2ce926bc-c255-4b04-b9f7-739933c01051/small/diagnos-systemes-medicaux-logo-fr.png https://guineabissauhealthbulletin.com/article/903166501-global-virus-network-launches-expanded-global-guardians-for-pandemic-preparedness-program-for-florida-high-school-students Guinea Bissau Health Bulletin en PressRelease 2026-04-01T15:42:00+00:00 Global Virus Network Launches Expanded “Global Guardians for Pandemic Preparedness” Program for Florida High School Students https://ml.globenewswire.com/media/6c1b2724-7b9b-469a-a7c3-bc0a64d716ae/small/gvn-lt-gr-gradiant-jpg.jpg https://guineabissauhealthbulletin.com/article/903154122-roto-rooter-completes-acquisitions-for-two-significant-territories Guinea Bissau Health Bulletin en PressRelease 2026-04-01T14:17:21+00:00 Roto-Rooter Completes Acquisitions for Two Significant Territories https://ml.globenewswire.com/media/1ab951c0-8d76-40e0-bc65-ebeaa1731e66/small/chemed-corp-logo-600x400-jpg.jpg https://guineabissauhealthbulletin.com/article/903152117-testicular-cancer-awareness-month-urges-men-don-t-drop-the-ball-check-yours Guinea Bissau Health Bulletin en PressRelease 2026-04-01T14:05:00+00:00 Testicular Cancer Awareness Month Urges Men: Don’t Drop the Ball—Check Yours https://ml.globenewswire.com/media/MDVmMDIwODItYmViZi00MjVmLTlmYjMtOGIzNGMwMjRlM2MwLTEyNzU5NzctMjAyNi0wNC0wMS1lbg==/tiny/Urology-Care-Foundation.png https://guineabissauhealthbulletin.com/article/903152565-origin-health-unveils-newly-redesigned-website-and-announces-open-registration-for-2nd-annual-guardian-initiative-charity-golf-tournament Guinea Bissau Health Bulletin en PressRelease 2026-04-01T14:00:00+00:00 Origin Health Unveils Newly Redesigned Website and Announces Open Registration for 2nd Annual Guardian Initiative Charity Golf Tournament https://ml.globenewswire.com/media/2ecdd836-8c58-4dd8-9d9a-57da2b45fdad/small/origin-logo-png.png https://guineabissauhealthbulletin.com/article/903152055-lumina-therapy-alliance-expands-to-the-bay-area-with-addition-of-san-francisco-stress-and-anxiety-center-approaching-400-clinicians-nationwide Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:40:00+00:00 Lumina Therapy Alliance Expands to the Bay Area with Addition of San Francisco Stress and Anxiety Center, Approaching 400 Clinicians Nationwide https://ml.globenewswire.com/media/046b4a15-6585-4d91-936e-8041854f2835/small/lumina-logo-li-1-png.png https://guineabissauhealthbulletin.com/article/903153735-progyny-commemorates-10-years-of-redefining-women-s-health-and-family-building-care Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:23:11+00:00 Progyny Commemorates 10 Years of Redefining Women’s Health and Family Building Care https://ml.globenewswire.com/media/1342dacd-99c3-4043-af8a-2fd5e9ea569f/small/progyny-203860-no-tag-png.png https://guineabissauhealthbulletin.com/article/903153438-extendicare-acquires-cbi-home-health Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:18:08+00:00 Extendicare Acquires CBI Home Health https://ml.globenewswire.com/media/6d631964-eede-4e2c-912c-58ab7d1dc35f/small/extendicare-jpg.jpg https://guineabissauhealthbulletin.com/article/903153265-nurexone-receives-first-place-in-healthcare-at-bold-awards-vii-and-engages-investor-brand-network-to-support-awareness-strategy Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:17:00+00:00 NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy https://ml.globenewswire.com/media/1514c671-cc84-4bcb-82d7-b834fce40882/small/nurexone-logo-rebrand-large-png.png https://guineabissauhealthbulletin.com/article/903153030-merit-medical-acquires-view-point-medical-inc-expanding-the-merit-therapeutic-oncology-portfolio Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:15:00+00:00 Merit Medical Acquires View Point Medical, Inc., expanding the Merit Therapeutic Oncology Portfolio https://ml.globenewswire.com/media/19958d8f-47a4-44f3-a780-247335a68768/small/merit-medical-systems-inc-logo.jpg https://guineabissauhealthbulletin.com/article/903142994-venus-concept-announces-completion-of-common-stock-sale-and-short-form-merger Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:02:00+00:00 Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger https://ml.globenewswire.com/media/e2cc3ec5-573b-4f8d-958f-718d93099bbd/small/image001-png.png https://guineabissauhealthbulletin.com/article/903138235-change-in-orion-group-executive-team-as-of-8-april-2026-berkeley-vincent-appointed-executive-vice-president-innovative-medicines Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:00:00+00:00 Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines https://ml-eu.globenewswire.com/media/8d7020d3-0f34-49aa-9ee5-654e8224808b/medium/berkeley-vincent.JPG https://guineabissauhealthbulletin.com/article/903138424-muutos-orion-konsernin-johtoryhm-ss-8-4-2026-lukien-berkeley-vincent-nimitetty-innovative-medicines-yksik-n-johtajaksi Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:00:00+00:00 Muutos Orion-konsernin johtoryhmässä 8.4.2026 lukien – Berkeley Vincent nimitetty Innovative Medicines -yksikön johtajaksi https://ml-eu.globenewswire.com/media/8d7020d3-0f34-49aa-9ee5-654e8224808b/medium/berkeley-vincent.JPG https://guineabissauhealthbulletin.com/article/903138871-a-decade-of-strength-muscular-dystrophy-association-and-burn-boot-camp-team-up-for-10th-annual-be-their-muscle-campaign Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:00:00+00:00 A Decade of Strength: Muscular Dystrophy Association and Burn Boot Camp Team Up for 10th Annual ‘Be Their Muscle’ Campaign https://ml.globenewswire.com/media/ZWZlMzNlNDQtNzVlYy00OWU0LWEzYzctYmFmYThlMzJjZmE2LTEwOTg0NjYtMjAyNi0wNC0wMS1lbg==/tiny/Muscular-Dystrophy-Association.png https://guineabissauhealthbulletin.com/article/903139436-nephros-expands-water-safety-capabilities-with-asse-12080-certified-water-management-planning-expertise Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:00:00+00:00 Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise https://ml.globenewswire.com/media/47f2ed6d-a81f-4174-a3eb-0a46a538285e/small/logo-png.png https://guineabissauhealthbulletin.com/article/903139608-paragonix-to-present-extensive-organ-transplant-research-at-the-46th-annual-international-society-of-heart-and-lung-transplantation-meeting Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:00:00+00:00 Paragonix to Present Extensive Organ Transplant Research at the 46th Annual International Society of Heart and Lung Transplantation Meeting https://ml.globenewswire.com/media/5b56fec1-dc1d-480e-8a0b-aa723d7e7cf9/small/paragonix-getinge-bluecenter-png.png https://guineabissauhealthbulletin.com/article/903140031-oncolytics-biotech-completes-domicile-change-to-the-united-states Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:00:00+00:00 Oncolytics Biotech® Completes Domicile Change to the United States https://ml.globenewswire.com/media/4dca5efc-ee4e-4e0a-b42d-7b45369d75da/small/oncy-jpg.jpg https://guineabissauhealthbulletin.com/article/903140636-noom-acquires-licensed-503a-pharmacy-accelerating-the-next-era-of-preventive-care-and-enabling-noom-s-expansion-beyond-weight-health Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:00:00+00:00 Noom Acquires Licensed 503A Pharmacy, Accelerating the Next Era of Preventive Care and Enabling Noom’s Expansion Beyond Weight Health https://ml.globenewswire.com/media/59427c88-907e-4c74-a192-a45c07ddbbf6/medium/noom-acquires-tmc.png https://guineabissauhealthbulletin.com/article/903140669-femasys-appoints-john-canning-as-chief-operating-officer-to-drive-operational-execution-and-advance-commercial-growth Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:00:00+00:00 Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth https://ml.globenewswire.com/media/c668c3db-ff7f-4eb5-b51a-b8db25e838b4/small/femasys-logo-2-jpg.jpg https://guineabissauhealthbulletin.com/article/903140724-beyond-air-expands-commercial-access-for-lungfit-ph-through-a-purchasing-agreement-with-a-top-3-national-group-purchasing-organization-gpo Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:00:00+00:00 Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO) https://ml.globenewswire.com/media/c7ae3957-2763-4e5c-9594-57e1ba60ed59/small/beyond-air-the-magic-of-breathing-png.png https://guineabissauhealthbulletin.com/article/903142707-j-star-holding-announces-return-of-jonathan-chiang-as-chief-executive-officer Guinea Bissau Health Bulletin en PressRelease 2026-04-01T13:00:00+00:00 J-Star Holding Announces Return of Jonathan Chiang as Chief Executive Officer https://ml.globenewswire.com/media/1a4c6faf-93be-4d28-a35f-1df9c4f0404e/small/j-star-logo-blue-transparent-png.png https://guineabissauhealthbulletin.com/article/903143057-johns-hopkins-health-plans-sits-down-with-dundalk-seniors-to-champion-community-connection Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:57:58+00:00 Johns Hopkins Health Plans Sits Down with Dundalk Seniors to Champion Community Connection https://ml.globenewswire.com/media/404affac-e9f4-456a-93bd-0ee405e6de49/small/johns-hopkins-logo-jpg.jpg https://guineabissauhealthbulletin.com/article/903141486-onemednet-onco-innovations-and-inka-health-announces-collaboration-aimed-to-accelerate-potential-for-oncology-drug-development-using-real-world-data Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:55:00+00:00 OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI https://ml.globenewswire.com/media/a356ae1d-a3c0-49e3-81b5-f19be76513d0/small/onemednet-jpg.jpg https://guineabissauhealthbulletin.com/article/903139065-senti-biosciences-announces-publication-in-cell-systems-demonstrating-advanced-logic-gated-car-design-for-cell-therapies Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:45:00+00:00 Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies https://ml.globenewswire.com/media/19732ef2-d354-4281-9dc5-6000f190dd83/small/sentibiologo-jpg.jpg https://guineabissauhealthbulletin.com/article/903140824-cannabix-technologies-announces-delivery-of-marijuana-breath-test-mbt-to-virginia-based-industrial-manufacturing-client Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:45:00+00:00 Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Virginia based Industrial Manufacturing Client https://ml.globenewswire.com/media/840bbe00-88ad-47fb-8fb5-0e2945da67d2/medium/cannabix-technologies-inc.jpg https://guineabissauhealthbulletin.com/article/903139028-polaryx-therapeutics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:30:00+00:00 Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/64e2f507-40e8-46aa-b22e-6661e7035467/small/polaryx-logonew-png.png https://guineabissauhealthbulletin.com/article/903139361-trimedx-named-a-top-100-finalist-in-the-2026-north-america-inspiring-workplaces-awards Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:30:00+00:00 TRIMEDX named a Top 100 finalist in the 2026 North America Inspiring Workplaces Awards https://ml.globenewswire.com/media/MDgwMjA4MTAtNjI1Ni00MjNkLThhNjgtZTI5YzIxNjNkY2M1LTExOTAzNjQtMjAyNi0wNC0wMS1lbg==/tiny/TRIMEDX.png https://guineabissauhealthbulletin.com/article/903139426-highridge-medical-announces-landmark-positive-policy-decision-for-the-tether-vertebral-body-tethering-system Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:30:00+00:00 Highridge Medical Announces Landmark Positive Policy Decision for The Tether™ Vertebral Body Tethering System https://ml.globenewswire.com/media/9ab08b53-05b0-40c5-b314-cc8184345a9b/small/highridge-only-stacked-blk-teal-png.png https://guineabissauhealthbulletin.com/article/903139446-feramax-is-canada-s-top-ranked-iron-supplement-for-11-consecutive-years Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:30:00+00:00 FeraMAX is Canada's Top-Ranked Iron Supplement for 11 Consecutive Years https://ml.globenewswire.com/media/3dded277-7953-4418-be63-7d7a3067811d/small/biosyent-logo-png.png https://guineabissauhealthbulletin.com/article/903139537-feramax-est-le-supplem-nt-de-fer-le-plus-recommand-au-canada-depuis-11-ann-es-cons-cutives Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:30:00+00:00 FeraMAX est le supplemént de fer le plus recommandé au Canada depuis 11 années consécutives https://ml.globenewswire.com/media/3dded277-7953-4418-be63-7d7a3067811d/small/biosyent-logo-png.png https://guineabissauhealthbulletin.com/article/903139597-clover-health-announces-departure-of-chief-financial-officer-and-appointment-of-interim-chief-financial-officer-reiterates-most-recently-issued Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:30:00+00:00 Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 https://ml.globenewswire.com/media/1a48a25b-b654-4d62-adb3-d1a776346264/small/clover-logo-green-rgb-jpg.jpg https://guineabissauhealthbulletin.com/article/903142310-actinogen-commences-open-label-phase-of-xanamia-alzheimer-s-trial-and-provides-business-update Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:30:00+00:00 Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update https://ml.globenewswire.com/media/e5165e23-ec4b-45f4-b198-93ce4f78d1c2/small/actinogen-logo-colour-750x750px-png.png https://guineabissauhealthbulletin.com/article/903142705-aprea-therapeutics-announces-closing-of-oversubscribed-30-million-private-placement Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:30:00+00:00 Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement https://ml.globenewswire.com/media/c63a19fa-f624-43d3-852f-d5956983aef3/small/aprea-logo-jpg.jpg https://guineabissauhealthbulletin.com/article/903142777-vireo-growth-inc-announces-closing-of-acquisition-of-eaze-inc Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:15:25+00:00 Vireo Growth Inc. Announces Closing of Acquisition of Eaze Inc. https://ml.globenewswire.com/media/d01c0dca-8260-48c8-8ead-e09111cf57b5/small/vireo-horizontalllogolockup-01-png.png https://guineabissauhealthbulletin.com/article/903139520-incision-free-mri-guided-prostate-treatment-with-profound-s-tulsa-pro-to-be-featured-in-multiple-presentations-at-the-upcoming-2026-society-of Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:15:00+00:00 Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting https://ml.globenewswire.com/media/94d9e057-9de3-430c-9a19-b41ff3e06a1e/small/profound-logo-cmyk-copy-jpg.jpg https://guineabissauhealthbulletin.com/article/903141302-vivosim-announces-pricing-of-up-to-a-4-million-public-offering Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:05:00+00:00 VivoSim Announces Pricing of up to a $4 Million Public Offering https://ml.globenewswire.com/media/636bff82-374b-4c96-8194-5345983eb76a/small/vivosim-logo-final-jpg.jpg https://guineabissauhealthbulletin.com/article/903139867-quantum-biopharma-submits-investigational-new-drug-ind-application-to-united-states-food-and-drug-administration-fda-for-lucid-ms-phase-two Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:02:00+00:00 Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis https://ml.globenewswire.com/media/e16adc7c-2200-4f53-bb33-b8dd37e4c1aa/medium/figure-1.jpg https://guineabissauhealthbulletin.com/article/903141432-rajani-dinavahi-md-appointed-chief-medical-officer-of-ardelyx Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:01:00+00:00 Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx https://ml.globenewswire.com/media/cee4ae6d-7a85-44bf-9c02-87e7fa934ec2/small/ardelyx-logo-rgb-jpg.jpg https://guineabissauhealthbulletin.com/article/903138869-remonihealth-expands-hardware-free-vision-as-a-service-platform-to-cover-over-90-of-chronic-eye-diseases Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 RemoniHealth Expands Hardware-Free "Vision-as-a-Service" Platform to Cover Over 90% of Chronic Eye Diseases https://ml.globenewswire.com/media/238363b4-a932-4baf-9eab-a195e142f04d/small/remoni-logo-color-final-x2023-01-png.png https://guineabissauhealthbulletin.com/article/903138947-stryker-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 Stryker to announce financial results for its first quarter of fiscal year 2026 https://ml.globenewswire.com/media/c24fe8bd-9db6-4f42-8a52-06a4e1b673b5/small/stryker-logo2015-jpg.jpg https://guineabissauhealthbulletin.com/article/903139062-electrocore-announces-publication-in-frontiers-in-neuroscience-highlighting-benefits-of-non-invasive-vagus-nerve-stimulation-in-patients-with-mild Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD https://ml.globenewswire.com/media/b80ed5b6-a449-461c-9034-85386286b09d/small/ec-logo-2018-tm-cmyk-jpg.jpg https://guineabissauhealthbulletin.com/article/903139189-alignment-healthcare-to-present-at-the-bofa-securities-health-care-conference-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 Alignment Healthcare to Present at the BofA Securities Health Care Conference 2026 https://ml.globenewswire.com/media/c6122501-032d-4425-bb0d-759ee3d3fe68/small/alignmenthealthcare-primary-logo-verticala-png.png https://guineabissauhealthbulletin.com/article/903139334-new-global-report-reveals-men-and-young-adults-driving-soaring-usage-of-wellness-technologies Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 New global report reveals men and young adults driving soaring usage of wellness technologies https://media.muckrack.com/press_releases/Hq/images/global-wellness-tech-trend-report2026_globalinsigh-bcb1d5cd-03a1-4b26-a.jpg https://guineabissauhealthbulletin.com/article/903139429-picard-medical-syncardia-to-participate-in-voice-of-the-patient-event-during-az-tech-week Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week https://ml.globenewswire.com/media/93c733bb-b54a-41af-856b-6d01c1f724a2/small/syncardia-x-picard-email-signature-2025-1-png.png https://guineabissauhealthbulletin.com/article/903139581-nanox-signs-distribution-agreement-with-elite-surgical-technologies-to-deploy-nanox-arc-in-key-u-s-markets Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 Nanox Signs Distribution Agreement with Elite Surgical Technologies to Deploy Nanox.ARC in Key U.S. Markets https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg https://guineabissauhealthbulletin.com/article/903140017-cogent-biosciences-announces-submission-of-new-drug-application-for-bezuclastinib-in-gastrointestinal-stromal-tumors-gist Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) https://ml.globenewswire.com/media/2b8cbfab-a4de-4e17-bdd6-7ef597a95d2e/small/cogent-biosciences-logo-rgb-png.png https://guineabissauhealthbulletin.com/article/903140042-synergy-chc-corp-reports-fourth-quarter-and-full-year-2025-financial-results Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results https://ml.globenewswire.com/media/e0c31e7c-6700-4800-a664-800eefcd7518/small/synergy-png.png https://guineabissauhealthbulletin.com/article/903140061-calidi-biotherapeutics-to-present-new-data-on-its-differentiated-approach-to-in-situ-t-cell-engagers-including-a-new-candidate-targeting-trop-2-at-the Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://guineabissauhealthbulletin.com/article/903140720-jenavalve-announces-the-start-of-commercialization-of-the-trilogy-transcatheter-heart-valve-system-in-the-united-states-the-first-and-only Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 JenaValve Announces the Start of Commercialization of the Trilogy® Transcatheter Heart Valve System in the United States - the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR) https://ml.globenewswire.com/media/a1ab2446-a463-4b8f-bc18-26a5ca117176/small/jv-logo-h-rgb-l-1607-png.png https://guineabissauhealthbulletin.com/article/903140762-cost-concerns-now-rival-fear-of-cancer-diagnosis-new-survey-finds Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 Cost concerns now rival fear of cancer diagnosis, new survey finds https://ml.globenewswire.com/media/35519942-f34e-46fc-8832-2984520de239/medium/prevent-cancer-foundation-s-2026-early-detection-survey.png https://guineabissauhealthbulletin.com/article/903141441-axe-compute-reports-12-million-in-executed-agreements-providing-835-thousand-in-estimated-monthly-income-entering-q2-2026 Guinea Bissau Health Bulletin en PressRelease 2026-04-01T12:00:00+00:00 Axe Compute Reports $12 Million in Executed Agreements Providing $835 Thousand in Estimated Monthly Income Entering Q2 2026 https://ml.globenewswire.com/media/0722059f-4d31-435e-974f-ff669a2cb2e4/small/axe-compute.png https://guineabissauhealthbulletin.com/article/903139519-trevi-therapeutics-to-participate-in-upcoming-events Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:30:00+00:00 Trevi Therapeutics to Participate in Upcoming Events https://ml.globenewswire.com/media/b97e9d57-6e8e-4570-87da-ea38c273f7c8/small/trevi-logo-jpg.jpg https://guineabissauhealthbulletin.com/article/903139943-dyne-therapeutics-announces-participation-at-2026-academy-of-managed-care-pharmacy-amcp-conference-to-begin-shaping-access-in-us-for-potential Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:30:00+00:00 Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg https://guineabissauhealthbulletin.com/article/903140040-medicus-pharma-ltd-clarifies-positive-skinject-phase-2-dataset Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:30:00+00:00 Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset https://ml.globenewswire.com/media/0f5af1d1-dfba-4810-baac-d1922c0558c1/small/medicus-logo-rgb-05-aspect-1500px-globe-newswire-2-jpg.jpg https://guineabissauhealthbulletin.com/article/903140675-avicanna-reports-full-year-2025-audited-financial-statements Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:30:00+00:00 Avicanna Reports Full Year 2025 Audited Financial Statements https://ml.globenewswire.com/media/6f98d5a4-c37e-4f97-9684-cb12bc90d2fd/medium/avicanna-reports-full-year-2025-audited-financial-statements.png https://guineabissauhealthbulletin.com/article/903140705-mink-therapeutics-announces-abstract-acceptance-for-presentation-at-the-american-thoracic-society-ats-2026-international-conference Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:30:00+00:00 MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference https://ml.globenewswire.com/media/6aa8e960-515a-40d6-9894-39ca47f5c84e/small/mink-logo-loyal-blue-and-light-blue-png.png https://guineabissauhealthbulletin.com/article/903141440-newcelx-announces-pricing-of-1-35-million-equity-financing-at-30-premium-pricing Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:21:00+00:00 NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing https://ml.globenewswire.com/media/ac801d4e-6ea5-4452-87c2-aa6a05bec73c/small/logo-positive-2x-jpg.jpg https://guineabissauhealthbulletin.com/article/903124332-a-kaleidoscope-inspires-the-foundation-for-sarcoidosis-see-sarcoidosis-global-campaign-for-sarcoidosis-awareness-month Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:04:00+00:00 A Kaleidoscope Inspires the Foundation for Sarcoidosis “See Sarcoidosis” Global Campaign for Sarcoidosis Awareness Month https://ml.globenewswire.com/media/990b35b6-bbe2-42c4-b32e-1bae87105b4a/medium/foundation-for-sarcoidosis-research-see-sarcoidosis.png https://guineabissauhealthbulletin.com/article/903124277-ocugen-announces-early-completion-of-dosing-in-phase-2-3-pivotal-confirmatory-trial-of-ocu410st-for-stargardt-disease Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:02:00+00:00 Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://guineabissauhealthbulletin.com/article/903124260-pasithea-therapeutics-announces-grant-of-fast-track-designation-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-nf1-associated-plexiform Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:01:00+00:00 Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity https://ml.globenewswire.com/media/0016f128-13c3-45a7-8455-cec1f4768995/small/pasithealogo-png.png https://guineabissauhealthbulletin.com/article/903123525-aavantgarde-appoints-philip-lao-as-senior-vice-president-of-business-development Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:00:00+00:00 AAVantgarde appoints Philip Lao as Senior Vice President of Business Development https://ml.globenewswire.com/media/e7ffd915-8158-436d-b9fe-8db1cb3597ce/small/logo-png.png https://guineabissauhealthbulletin.com/article/903123945-soleo-health-selected-as-an-authorized-specialty-pharmacy-of-qivigy-for-primary-humoral-immunodeficiency-pi-treatment Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:00:00+00:00 Soleo Health Selected as an Authorized Specialty Pharmacy of QIVIGY® For Primary Humoral Immunodeficiency (PI) Treatment https://ml.globenewswire.com/media/b3c4bcdc-fa25-4f50-8b81-09f13e80a008/small/soleo-logo-1024-x-1024-png.png https://guineabissauhealthbulletin.com/article/903124064-rapport-therapeutics-to-present-new-phase-2-treatment-follow-up-data-for-rap-219-in-focal-onset-seizures-at-the-2026-american-academy-of-neurology Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:00:00+00:00 Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting https://ml.globenewswire.com/media/7777ee9b-f88b-4a59-a668-d81520f9d32c/small/rapport-logo-color-rgb-png.png https://guineabissauhealthbulletin.com/article/903124214-tilray-brands-delivers-record-q3-fiscal-2026-results-net-revenue-increases-to-207-million-with-11-organic-growth-and-gross-profit-expands-to-55 Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:00:00+00:00 Tilray Brands Delivers Record Q3 Fiscal 2026 Results; Net Revenue Increases to $207 Million with 11% Organic Growth and Gross Profit Expands to $55 Million, Increasing 6% Year-Over-Year https://ml.globenewswire.com/media/2dbf85bb-5e30-4623-8f9b-931442240c05/small/tilraybrands-logo-fullcolor-rbg-horiz-01-png.png https://guineabissauhealthbulletin.com/article/903124285-axsome-therapeutics-acquires-selective-pde10a-inhibitor-balipodect-for-the-treatment-of-schizophrenia-and-other-neuropsychiatric-conditions Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:00:00+00:00 Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions https://ml.globenewswire.com/media/1186f248-bfb6-4258-a391-f2ffd94c5d76/small/axsome-r-morpheus-logo-pos-rgb-png.png https://guineabissauhealthbulletin.com/article/903124295-ocular-therapeutix-to-present-additional-sol-1-data-and-analyses-at-upcoming-scientific-conferences-in-april Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:00:00+00:00 Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://guineabissauhealthbulletin.com/article/903124296-bioxcel-therapeutics-announces-food-drug-administration-acceptance-of-supplemental-new-drug-application-for-use-of-igalmi-in-the-at-home-setting Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:00:00+00:00 BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting https://ml.globenewswire.com/media/63fea215-2cfc-4e2b-b169-43dcfff60b34/small/btai-logo-png-220x123-png.png https://guineabissauhealthbulletin.com/article/903124589-apollomics-inc-announces-2-0-million-bridge-financing Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:00:00+00:00 Apollomics Inc. Announces $2.0 Million Bridge Financing https://ml.globenewswire.com/media/5d278096-e1c2-4350-b583-bca455f23b4b/small/apollomics-color-logo-1147x445-jpg.jpg https://guineabissauhealthbulletin.com/article/903124698-newgen-filed-2025-annual-report-on-form-20-f Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:00:00+00:00 NewGen Filed 2025 Annual Report on Form 20-F https://ml.globenewswire.com/media/NjJiZDM3MTctMDVjNC00NjQwLTllOTYtYThjY2ViMTI2OTljLTEyOTcwMTEtMjAyNi0wNC0wMS1lbg==/tiny/NewGenIvf-Limited.png https://guineabissauhealthbulletin.com/article/903124732-tiziana-announces-data-showing-nasal-anti-cd3-improves-cognition-associated-with-aging Guinea Bissau Health Bulletin en PressRelease 2026-04-01T11:00:00+00:00 Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging https://ml.globenewswire.com/media/991c340c-a083-4bcb-ad41-e7eea83f6f97/small/tiziana-logo-png.png https://guineabissauhealthbulletin.com/article/903124311-kala-bio-engages-dr-saeid-babaei-as-senior-scientific-advisor-to-evaluate-clinical-assets-and-precision-development-opportunities Guinea Bissau Health Bulletin en PressRelease 2026-04-01T10:45:00+00:00 Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities https://ml.globenewswire.com/media/15db4366-93ba-40fa-b80d-58cbdde3496e/small/kala-bio-logo-jpg.jpg https://guineabissauhealthbulletin.com/article/903124396-zymeworks-appoints-kristin-stafford-as-chief-financial-officer Guinea Bissau Health Bulletin en PressRelease 2026-04-01T10:00:00+00:00 Zymeworks Appoints Kristin Stafford as Chief Financial Officer https://ml.globenewswire.com/media/de376a45-7a16-49db-8ad4-65ff45472c90/small/zymeworks-logo-color-png.png https://guineabissauhealthbulletin.com/article/903095938-major-shareholder-announcement Guinea Bissau Health Bulletin en PressRelease 2026-04-01T07:24:36+00:00 Major Shareholder Announcement https://ml-eu.globenewswire.com/media/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce/small/logo-jpg.jpg https://guineabissauhealthbulletin.com/article/903096463-onward-medical-publishes-convocation-of-the-2026-annual-general-meeting-of-shareholders-and-proposed-resolutions Guinea Bissau Health Bulletin en PressRelease 2026-04-01T06:45:00+00:00 ONWARD Medical Publishes Convocation of the 2026 Annual General Meeting of Shareholders and Proposed Resolutions https://ml.globenewswire.com/media/a60261ec-0c66-4acb-8726-e567073990a2/small/onwardresized1-png.png https://guineabissauhealthbulletin.com/article/903096765-askbio-announces-completion-of-enrollment-in-phase-2-clinical-trial-of-ab-1002-investigational-gene-therapy-for-heart-failure Guinea Bissau Health Bulletin en PressRelease 2026-04-01T06:40:29+00:00 AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure https://ml.globenewswire.com/media/MGNkMTI0NzQtMTgzNC00MjgxLWE3ZGYtM2E2Nzk5Yzc3ZTUyLTEyODY3MTItMjAyNi0wNC0wMS1lbg==/tiny/Asklepios-BioPharmaceutical-In.png